Related Experiment Video
Updated: Mar 29, 2026
A Preclinical Murine Model of Hepatic Metastases
Published on: September 27, 2014
Establishment of Gemcitabine-resistant Mouse Pancreatic Ductal Adenocarcinoma Cell Line and Possible Therapeutic
Kumiko Miyashita1, Kimihiro Yamashita1, Makoto Miyoshi1
1Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan.
Background/Aim:
Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal due to gemcitabine (GEM) resistance. This study aimed to establish a clinically relevant immunocompetent model to identify novel mediators of acquired GEM resistance.
Materials And Methods:
Metastatic PDAC (mPDAC) cells, generated from CD133-positive pancreatic stem cells (mutant Trp53, Cdk4, Kras), were subjected to chronic in vivo GEM selection to establish a line with reduced sensitivity (mPDAC-R).
Results:
mPDAC-R exhibited sustained growth under GEM treatment, alongside enhanced invasiveness and metastatic potential. Transcriptomic profiling identified monoamine oxidase B (MAOB) as an up-regulated mediator. Pharmacological inhibition of MAOB significantly suppressed proliferation and tumor growth in both mPDAC-R and human PDAC cell lines.
Conclusion:
We established a novel GEM-resistant mPDAC model and identified MAOB as a promising therapeutic target. These findings provide a rationale for targeting MAOB-driven survival signals to overcome chemoresistance in refractory pancreatic cancer.
Insights
Researchers developed a gemcitabine-resistant pancreatic cancer model. They identified monoamine oxidase B (MAOB) as a key target, showing its inhibition effectively reduces tumor growth and overcomes chemoresistance.
Area of Science:
- Oncology
- Cancer Biology
- Drug Resistance
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with significant gemcitabine (GEM) resistance.
- Acquired GEM resistance is a major clinical challenge in treating metastatic PDAC (mPDAC).
Purpose of the Study:
- To establish a clinically relevant immunocompetent model for studying acquired GEM resistance in PDAC.
- To identify novel molecular mediators contributing to GEM resistance in PDAC.
Main Methods:
- Generated metastatic PDAC (mPDAC) cells from pancreatic stem cells with specific mutations (Trp53, Cdk4, Kras).
- Developed a GEM-resistant cell line (mPDAC-R) through chronic in vivo GEM selection.
- Utilized transcriptomic profiling to identify key mediators of resistance.
Main Results:
- The mPDAC-R model demonstrated sustained growth, increased invasiveness, and metastatic potential under GEM treatment.
- Monoamine oxidase B (MAOB) was identified as a significantly up-regulated mediator in mPDAC-R cells.
- Pharmacological inhibition of MAOB effectively suppressed proliferation and tumor growth in both the mPDAC-R and human PDAC cell lines.
Conclusions:
- A novel GEM-resistant mPDAC model was successfully established.
- MAOB was identified as a promising therapeutic target for overcoming GEM resistance in pancreatic cancer.
- Targeting MAOB-driven survival pathways offers a potential strategy to treat refractory pancreatic cancer.
